Sumitovant Biopharma

Sumitovant is the parent company of five biopharmaceutical companies: Myovant, Urovant, Enzyvant, Altavant and Spirovant. Our companies have a robust pipeline of innovative drug treatments targeting a broad range of diseases. With a technology-enabled approach to drug discovery, development and commercialization, we remove friction from the process of bringing promising new compounds to market.

Sumitovant’s Digital Innovation approach integrates key skill sets, data sets and analytic tools to provide real answers to pharma’s most critical questions.  With our tech-enabled approach to drug discovery, development and commercialization, we remove friction and accelerate every aspect of the process to bring promising new compounds to market.

Sumitovant is wholly owned by Sumitomo Dainippon Pharma. Together, the Sumitomo Dainippon Pharma group of companies closely collaborate to expedite the discovery, development, and commercialization of truly innovative treatments. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes and shareholder return.

New York, NY
Biotechnology
201-500 employees
Founded 2019

Opportunities at Sumitovant Biopharma